US › Healthcare

Atrium Therapeutics, Inc. Common Stock (RNA)

US · Healthcare · Biotechnology

$9.56+0.63%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$3.0M

Revenue YoY

-21.9%

Net profit

$-20.2M

EPS

$-1.18

EPS estimate

$-0.64

Net margin

-672.0%

EPS came in at -1.18 against a street estimate of -0.64 — a miss of 84.4%.

Key statistics

Market cap

$177.0M

Forward P/E

0.0

P/B

0.84

Book value

$12.54

EPS (TTM)

$-5.36

52-week high

$16.77

52-week low

$10.00

50-day MA

$12.56

200-day MA

$13.04

Beta

0.93

Analyst view

Analysts rate Atrium Therapeutics, Inc. Common Stock a strong buy (15 buy, 0 hold, 0 sell out of 15) with an average price target of $25.00.

Shareholding

Insiders

4.27%

Institutions

84.44%

Largest institutional holders

Fund	Stake
CIBC Bancorp USA Inc.	0.00%
Arizona State Retirement System	0.00%
Capital Analysts Inc.	0.00%
Acadian Asset Management LLC	0.00%
Carmignac Gestion	0.00%
Allianz Asset Management AG	0.00%
Cinctive Capital Management LP	0.00%
ARP AMERICAS LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atrium Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.